Therapeutic vaccination against chronic viral infection: the importance of cooperation between CD4+ and CD8+ T cells

https://doi.org/10.1016/S0952-7915(98)80119-2Get rights and content

Abstract

The goal of therapeutic vaccination is to elicit an antiviral immune response within persistently infected individuals and consequently eradicate the infection. CD8+ T cells are potent mediators of viral clearance; however, during chronic infections CD4+ T cell help is required to sustain antiviral CD8+ T cell activity. Therapeutic vaccination should be targeted towards enhancing both CD4+ and CD8+ T cell virus-specific responses.

References (53)

  • B Odermatt et al.

    Virus-triggered acquired immunodeficiency by cytotoxic T-cell-dependent destruction of antigen-presenting cells and lymph follicle structure

    Proc Natl Acad Sci USA

    (1991)
  • H Ploegh

    Viral strategies of immune evasion

    Science

    (1998)
  • MJ Smyth et al.

    The relative role of lymphocyte granule exocytosis versus death receptor-mediated cytotoxicity in viral infections

    J Virol

    (1998)
  • MT Heemels et al.

    Generation, translocation and presentation of MHC class I-restricted peptides

    Annu Rev Biochem

    (1995)
  • D Kägi et al.

    Molecular mechanisms of lymphocyte-mediated cytotoxicity and their role in immunological protection and pathogenesis in vivo

    Annu Rev Immunol

    (1996)
  • LL Carter et al.

    Relative perforin- and Fas-mediated lysis in T1 and T2 CD8+ effector populations

    J Immunol

    (1995)
  • S Sad et al.

    Cytokine-induced differentiation of precursor mouse CD8+ T cells into cytotoxic CD8+ T cells secreting Th1 or Th2 cytokines

    Immunity

    (1995)
  • TR Mosmann et al.

    Functions of CD8+ T-cell subsets secreting different cytokine patterns

    Semin Immunol

    (1997)
  • BD Jamieson et al.

    Effective clearance of a persistent viral infection requires cooperation between virus-specific Lyt2+ T cells and nonspecific bone marrow-derived cells

    J Virol

    (1987)
  • BD Jamieson et al.

    Abrogation of tolerance to a chronic viral infection

    J Immunol

    (1991)
  • F Lehmann-Grube et al.

    Mechanism of recovery from acute virus infection. I. Role of T lymphocytes in the clearance of lymphocytic choriomeningitis virus from spleens of mice

    J Immunol

    (1985)
  • D Moskophidis et al.

    Mechanism of recovery from acute virus infection: treatment of lymphocytic choriomeningitis virus-infected mice with monoclonal antibodies reveals that Lyt-2+ T lymphocytes mediate clearance of virus and regulate the antiviral antibody response

    J Virol

    (1987)
  • DG Quinn et al.

    The cell-mediated immune response against lymphocytic choriomeningitis virus in β2-microglobulin deficient mice

    Immunol Rev

    (1995)
  • D Kägi et al.

    Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice

    Nature

    (1994)
  • CM Walsh et al.

    Immune function in mice lacking the perforin gene

    Proc Natl Acad Sci USA

    (1994)
  • A Tishon et al.

    An essential role for type 1 interferon-γ in terminating persistent viral infection

    Virology

    (1995)
  • Cited by (106)

    • MHC class II restricted neoantigen: A promising target in tumor immunotherapy

      2017, Cancer Letters
      Citation Excerpt :

      A recent study suggested that IFN-γ, synergistically with TNF-α, directly induced senescence-defining permanent growth arrest in tumors (Fig. 1E) [38]. Continuous loss of CD8+T cells was observed in the absence of CD4+ T cells, resulting in failure to resist following viral challenge, which suggests CD8+T cells can hardly take effect without the help of CD4+ T cells [39,40]. But it is still uncertain whether CD4+ T cells can exert an antitumor effect independently.

    • Immunological challenges for peptide-based immunotherapy in glioblastoma

      2014, Cancer Treatment Reviews
      Citation Excerpt :

      In addition to an HLA class I initiated cytotoxic T cell responses, recent investigations have emphasized the role of CD4+ Thelper cells in priming anti-tumor responses after vaccination [101]. In parallel to other complex immune response, i.e. viral infections [102], CD8+ and CD4+ Thelper cell interaction is mandatory for efficient anti-tumor immunity, e.g. by escaping activation-induced CTL cell death or supporting the formation of long-term memory [103,104]. Although the role of CD4+ Thelper cells is being discussed controversially [105], we assume that a vaccinating agent should include tumor-associated peptides, which can bind to HLA class II molecules and promote a tumor-specific involvement of CD4+ Thelper cells.

    View all citing articles on Scopus
    View full text